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Genetic and constitutional 
factors are major contributors to 
substantia nigra hyperechogenicity
Juan F. Vázquez-Costa  1,2,3, José I. Tembl4, Victoria Fornés-Ferrer5, Fernando Cardona  6,7, 
Lluis Morales-Caba4, Gerardo Fortea4, Jordi Pérez-Tur  6,7,8 & Teresa Sevilla  1,2,3,9
Hyperechogenicity of substantia nigra (SNh) is a frequent finding in amyotrophic lateral sclerosis (ALS), 
Parkinson’s disease (PD) and other movement disorders (MD) patients, but its meaning is unclear. To 
ascertain the contribution of different factors to SNh area, we measured it in 108 ALS, 102 PD, 91 other 
MD patients and 91 healthy controls. Demographical data were collected in all patients and controls. 
In ALS patients, we also recorded clinical variables, performed genetic analysis and measured baseline 
levels of ferritin. After family history and genetic testing, ALS patients were classified as familial (15) 
or sporadic (93). ALS, PD and other MD patients had a larger SNh area than controls. Left SNh and 
male gender, but not age, associated with larger SNh area in both patients and controls. Familial ALS 
patients showed larger SNh area than sporadic ones and familial ALS was the only clinical variable in 
the multivariate analysis to be associated with larger SNh area in ALS patients. Our results suggest 
that SNh associates with genetic and constitutional factors (male gender, handedness), some of which 
predispose to certain neurodegenerative diseases. This evidence supports the idea of SNh as an inborn 
marker of unspecific neuronal vulnerability.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease clinically characterised by progressive weak-
ness, and by signs of upper (UMN) and lower motor neuron (LMN) impairment. Three different phenotypes 
can be distinguished according to the degree of clinical impairment of UMN and LMN1: classical ALS (cALS), 
primary lateral sclerosis (PLS) and progressive muscular atrophy (PMA). Pathologically, ALS is characterised by 
TDP-43 aggregates found in degenerating UMN and LMN1. However, TDP-43 deposits and a variable degree of 
neuronal loss can be found far beyond motor neurons in many ALS patients; e.g., substantia nigra (SN) in about 
50% of them2, 3. The extension of these deposits probably accounts for the presence or absence of extra-motor 
features, such as cognitive or behavioural impairment in ALS patients1.
By means of transcranial sonography (TCS), a larger area of increased echogenicity (hyperechogenicity) in 
SN has been found in patients with different neurodegenerative diseases (especially in Parkinson’s disease, PD) 
compared to controls4. This SN hyperechogenicity (SNh) is thought to reflect increased iron deposits5. Although 
its exact meaning remains unknown, it has been proposed to be a marker of SN degeneration or vulnerability5. 
Recently, SNh has been reported in 50–70% of cALS patients6–9, but whether in ALS this finding also reflects 
vulnerability of the nigrostriatal system or the pathologic spread of the disease to the SN is not known. Moreover, 
SNh has not been studied in other phenotypes (PMA or PLS) or in familial ALS.
The aim of this study was to evaluate the SNh in ALS patients (including PMA and PLS) compared to move-
ment disorders (MD) patients and healthy controls. We also aimed to evaluate the contribution of demographical, 
clinical, biochemical and genetic factors to SNh in patients and controls.
1Neuromuscular Research Unit, Instituto de Investigación Sanitaria la Fe (IIS La Fe), Valencia, Spain. 2ALS Unit, 
Department of Neurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. 3Centro de Investigación 
Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain. 4Neurosonology Laboratory, Department of 
Neurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. 5Biostatistics Unit, Instituto de Investigación 
Sanitaria la Fe (IIS La Fe), Valencia, Spain. 6Laboratory of Molecular Genetics, Institut de Biomedicina de València-
CSIC, Valencia, Spain. 7Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas 
(CIBERNED), Valencia, Spain. 8Unidad mixta de Neurología y Genética, Instituto de Investigación Sanitaria la Fe 
(IIS La Fe), Valencia, Spain. 9Department of Medicine, University of Valencia, Valencia, Spain. Correspondence and 
requests for materials should be addressed to J.F.V.-C. (email: juan.vazquez.neuro@gmail.com)
Received: 3 February 2017
Accepted: 30 June 2017
Published online: 2 August 2017
OPEN
www.nature.com/scientificreports/
2SCIENtIFIC RePoRTS | 7: 7119 | DOI:10.1038/s41598-017-07835-z
Methods
Subjects and definitions. For this cross-sectional study, patients diagnosed with classical ALS (cALS), 
PMA or PLS who came to our ALS Unit between February 2014 and September 2016 and gave written informed 
consent, were recruited. Patients are routinely evaluated by the same neurologist (JFVC), and demographical and 
clinical data are prospectively recorded in a database. The cALS patients met the El Escorial revised criteria of 
possible, probable or definitive ALS10. PMA was defined as a progressive isolated impairment of LMN in at least 
two regions11, and PLS as a progressive isolated impairment of UMN in at least one region other than the lumbar 
region12.
For comparison purposes, we included a previously reported cohort of subjects without neurodegenerative 
diseases13. We also included patients with MD in whom an increased SNh area had been previously reported14–16: 
PD, atypical parkinsonism, vascular parkinsonism and essential tremor. The data of a subset of these patients have 
also been previously published17.
Family history and genetic analysis. ALS patients were systematically asked for family history of ALS, 
dementia or parkinsonism of any kind in first- or second-degree relatives. When the history of dementia was 
compatible with frontotemporal dementia (FTD), medical records of this relative were reviewed (whenever avail-
able). Patients were categorised as familial ALS (fALS) whenever they met the criteria for possible, probable or 
definite ALS18, or as sporadic ALS (sALS) when not. Both sALS and fALS patients were screened for C9ORF72 
with repeat primed PCR, as previously reported19. In those fALS patients not carrying a C9ORF72 expansion, 
SOD1, TARDBP and FUS genes were subsequently analysed by Sanger sequencing. After the genetic analysis, 
fALS grades were appropriately reassessed18.
Clinical and analytical variables. Age, gender, time of symptom onset, region of onset (bulbar and spinal), 
side of onset (or side predominance in bulbar onset cases) and body mass index before disease onset (premorbid 
BMI) were recorded for all ALS patients.
ALS patients were examined at the time of recruitment, and the following items were recorded: parkinsonism 
signs, disability (ALSFRS-R)20, and degree of UMN impairment (UMN score) for a maximum of 1621.
Executive and behavioural examination were performed in a subset of 100 patients. Executive function was 
assessed with digit span; verbal fluency index22 and stroop test in patients without relevant bulbar symptoms; 
and trail A and B in patients without symptoms in the dominant hand. Patients were studied with at least two 
different executive tests, depending on their disability. Mild executive impairment was diagnosed according to 
current criteria22. Relatives were systematically asked for behavioral symptoms following Rascovsky criteria and 
mild behavioural impairment and FTD were diagnosed according to current criteria22. Moreover, 60 patients 
were assessed with the Spanish validated version of the Frontal Systems Behaviour Scale (FrSBe)23, fulfilled by the 
caregiver. The FrSBe has three subscales: apathy, disinhibition, and executive dysfunction. For the present study, 
we have considered the Z-scores of the post-illness forms.
The basal (within two months from recruitment) levels of ferritin were determined in 98 patients by immuno-
turbidimetry on a Beckman Coulter AU 5400 according to manufacturer’s instructions.
TCS examination. A TCS examination was performed by an expert neurologist sonographer (JIT), who was 
blind to the clinical data, with the same ultrasound system (Toshiba Aplio XG, Tokyo, Japan 2008) equipped with 
a 2.5 MHz phased-array transducer to obtain B-mode images through a temporal acoustic bone window. Right 
and left SNh were obtained and measured by this examiner, as previously published13.
Statistical analysis. Differences in the right and left SNh areas in patients and controls (age- and 
gender-adjusted) were assessed with a linear mixed regression model. Differences in the SNh area in fALS and 
sALS were assessed by the Wilcoxon test, and the relationship between SNh and ferritin, verbal fluency index 
and FrSBe Z-scores was assessed by Pearson’s correlation. To assess the effect of side of disease onset on the 
size of contralateral SNh, linear model regression was performed, which included an interaction between these 
covariates. An association of the demographical and clinical variables of the ALS patients with SNh area on both 
sides was assessed by a mixed linear regression model. In this model was assumed that SNh area depended on 
fixed effects (covariates) and random effects due to inter-individual variability. Firstly, a group of covariates (age, 
gender, family history, fALS, premorbid BMI, disease duration, phenotype, ALSFRS-R, executive or behavioural 
impairment, parkinsonism and SNh side) were pre-selected based on previous literature and the study goal. 
Finally, the combination of covariates that best fitted the model was selected according to the Akaike Information 
Criteria (AIC). P values of <0.05 were considered statistically significant. All the statistical analyses and graphs 
were performed using version 3.2.2 of the R software.
Ethical approval. The study was approved by the Ethics Committee for Biomedical Research of the La Fe 
Hospital (Valencia, Spain) and has been conducted according to the principles of the Declaration of Helsinki. All 
the participants gave written informed consent.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
Population characteristics. One hundred and eight ALS patients (74.1% cALS, 15.7% PMA and 10.2% 
PLS) and 193 MD patients (102 PD and 91 with other MD) were recruited for this study. Ninety-one healthy 
controls, in whom at least one SNh was measureable, were also included. Overall ALS patients were moder-
ately disabled and the time since symptoms onset ranged between 17 months in ALS to 49 months in PLS. The 
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demographical and ultrasound characteristics of both patients and controls, and the clinical and genetic charac-
teristics of ALS patients as per phenotype, are summarised in Table 1.
Family history and genetic analysis. Unspecified dementia was the most frequently reported family his-
tory in ALS patients, followed by ALS or FTD (Table 1). Thirteen (12%) ALS patients of 11 different families 
(three members of one family were included in the study) were classified as fALS as per history18. A pathologic 
expansion in C9ORF72 was found in seven of the 11 (64%) index fALS cases. A SOD1 mutation was found 
in three index fALS cases (p.E22G and p.N139H) and in two affected relatives of the index case carrying the 
p.N139H mutation. No mutations were identified in one fALS case. C9ORF72 was found in two of the 95 sporadic 
cases (2%). Consequently, 15 ALS patients (13.9%) were, after genetic analysis, classified as fALS18.
SNh area in patients and controls. It was possible to measure SNh area through the temporal acoustic 
bone window in at least one side in 97 (89.8%) ALS patients (including 12 of 15 fALS patients, 80%), 93 (91.2%) 
PD patients and 73 (80.2%) patients with other MD.
cALS, PMA and PLS patients and the MD patients showed a larger SNh area than the healthy controls. The 
largest mean and median SNh areas were found in PD patients and the smallest ones in PLS patients (Table 1). 
Left SNh area was greater than the right one in all cohorts, except in PMA patients (Table 1, Fig. 1). Based on 
our previous report13, hyperechogenicity of SN (SNh+) was considered whenever one SNh area was larger than 
0.22 cm2, whereas SNh− was considered whenever both areas were smaller than 0.22 cm2. Patients with only one 
visible SNh area, which was <0.22 cm2 were excluded because their classification was uncertain. Accordingly, 
SNh+ was found in 56.7% of ALS patients compared to 8.8% of healthy controls (Table 1).
Contribution of demographical variables to SNh area in patients and controls. In the multivari-
ate analysis, differences in SNh area between ALS patients and the MD controls on one side and healthy controls 
on the other were statistically significant after adjusting for age, gender and side of SNh (Table 2). Left SNh and 
male gender, but not age, were associated with a larger SNh area in the multivariate analysis (Table 2). This effect 
of male gender and left side was apparent in each subgroup of patients and controls (Table 1, Fig. 1).
Associaton of demographical, clinical and biochemical variables with SNh area in the ALS 
patients. Age, gender, mutations, familial history and disease duration showed differences in the SNh+ com-
pared to the SNh− ALS patients (Table 3). Conversely, no differences in disease characteristics were apparent, 
except for executive or behavioural impairment and parkinsonism, which were slightly more frequent in the 
SNh+ patients.
In the univariate analysis, fALS patients presented a larger SNh area than the sporadic patients (0.20 vs. 0.28, 
p = 0.01). This effect appeared to be independent of the causing mutation (Fig. 2). However, no correlation was 
found between the SNh and basal levels of ferritin in the ALS patients (R = −0.0005, p = 0.99) nor between SNh 
and verbal fluency index or any of the FRSBe subscales (Supplementary Table 1).
We found no effect of disease lateralisation on the size of contralateral SNh in ALS patients (estimate = −0.004, 
p = 0.91), and the left SNh area appeared to be larger independently of side of disease onset (Supplementary 
Table 2 and Supplementary Figure 1).
In the multivariate analysis, we first analysed all the pre-selected covariates. Subsequently, we repeated the 
analysis after removing those covariates that were not found to be significant in the first model, and for which 
there were no previous evidences of association with SNh (parkinsonism, ALSFRS-R, cognitive or behavioural 
impairment, disease duration and premorbid BMI). The model showed notable improvement (AIC −161 vs. 
−233). In this final model, fALS was the only variable that was significantly associated with a larger SNh area in 
ALS patients, but a trend to negative association for PLS and to positive association for left SNh side (Table 4) 
were observed.
Discussion
Firstly thought to be a marker of neuronal degeneration in the SN, more recent studies suggest the SNh role 
as a marker of SN vulnerability5, 24. Our study strongly reinforces this hypothesis and adds further evidences 
that genetic and constitutional factors are key to predispose to SNh in different neurodegenerative diseases and 
controls.
We studied a cross-sectional cohort of patients in an ALS Unit of a tertiary centre in Spain. This explains 
why some phenotypes (PMA and PLS) and fALS cases can be slightly overrepresented compared to prospective 
population-based studies. Rates of fALS and causing mutations in our cohort were similar to those previously 
described in European population25.
In our study, SNh area was found larger in all the studied diseases compared to healthy controls after adjust-
ing for age and gender. PD patients presented the largest area, whereas patients with other MD and PLS patients 
had the smallest SNh area. Although an increased SNh area was first described in PD patients, it has also been 
found in other MD14–16, as well as in neurodegenerative diseases not typically characterised by SN degeneration 
or vulnerability, such as ALS or Friedreich’s ataxia7, 8, 26. Our data are consistent with those reports showing that, 
although PD patients are those with larger SNh, SN+ is also a frequent finding in different ALS phenotypes and 
other MD.
Male gender strongly associated with a larger SNh area in the entire population, and this association was 
apparent for each studied cohort. However, they lost significance when analysed only in ALS patients and 
together with other clinical variables, which also influenced SNh area. This is probably the result of having a lower 
statistical power due to the reduced sample size, since a trend of this effect was still evident. The effect of male 
gender on SNh area has been previously reported in PD and controls5, 24, 27, which further supports our results. 
Interestingly, male gender is more overrepresented in PD, cALS and PMA, but not in PLS24, 28. This suggests that 
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cALS (n = 80) PMA (n = 17) PLS (n = 11) PD (n = 102) OMD (n = 91) Controls (n = 91)
Age (years)
   Mean (SD) 61.75 (12.26) 63.98 (13.2) 64.71 (11.68) 77.1 (88.15) 70.98 (9.58) 66.92 (12.7)
   Median (IQR) 61.37 (54.93, 71.13) 65 (59.76, 72.07) 68.48 (58.95, 73.07) 70 (62.25, 74) 72 (65, 79) 69 (59, 76)
Gender (male)
   n (%) 45 (56.2%) 15 (88.2%) 8 (72.7%) 60 (58.8%) 51 (56%) 67 (73.6%)
Premorbid BMI, n = 102
   Mean (SD) 27.61 (4.53) 27.78 (4.49) 27.13 (3.64)
   Median (IQR) 27.24 (24.68, 29.76) 26.53 (24.67, 30.58) 28.07 (24.75, 29.52)
Family history
   Dementia n (%) 10 (12.5%) 3 (17.6%) 0 (0%)
   PD n (%) 3 (3.8%) 0 (0%) 0 (0%)
   Dementia and PD n (%) 3 (3.8%) 0 (0%) 0 (0%)
   ALS or FTD n (%) 10 (12.5%) 3 (17.6%) 1 (9.09%)
Region of onset
   Bulbar n (%) 22 (27.5%) 1 (5.9%) 3 (27.3%)
   Spinal n (%) 58 (72.5%) 16 (94.1%) 8 (72.7%)
Side of onset or side predominance, n = 106
   Right n (%) 33 (41.2%) 8 (47.1%) 3 (27.3%)
   Left n (%) 36 (45%) 5 (29.4%) 5 (45.5%)
   Symmetric n (%) 10 (12.5%) 3 (17.6%) 3 (27.3%)
Parkinsonism
   n (%) 4 (5%) 0 (0%) 1 (9.1%)
Time from onset (months)
   Mean (SD) 23.46 (20.05) 42.69 (42.57) 75.38 (66.6)
   Median (IQR) 16.75 (8.78, 29.82) 25.03 (14.07, 55.8) 48.83 (37.45, 99.1)
ALSFRS-R
   Mean (SD) 34.91 (7.74) 37.71 (6.72) 32.3 (7.21)
   Median (IQR) 35 (31, 41.25) 39 (36, 43) 34.5 (29.25, 36.75)
UMN score
   Mean (SD) 5.23 (5.03) 0 (0) 12.4 (3.03)
   Median (IQR) 3 (1, 9) 0 (0, 0) 13.5 (12.25, 14)
EB impairment (n = 100)
   No 46 (61.3%) 12 (80%) 3 (30%)
   Mild 24 (32%) 3 (20%) 7 (70%)
   FTD 5 (6.7%) 0 (0%) 0 (0%)
Mutation carriers
   C9ORF72 8 (10%) 0 (0%) 1 (9.09%)
   SOD1 2 (2.5%) 3 (17.6%) 0 (0%)
   Familial ALS 11 (13.7%) 3 (17.6%) 1 (9.09%)




   Mean (SD) 0.2 (0.13) 0.21 (0.1) 0.14 (0.08) 0.24 (0.13) 0.16 (0.11) 0.07 (0.08)
   Median (IQR) 0.18 (0.11, 0.26) 0.19 (0.18, 0.26) 0.09 (0.08, 0.18) 0.24 (0.15, 0.3) 0.15 (0.08, 0.24) 0.06 (0, 0.11)
Left SNh area
   Mean (SD) 0.23 (0.12) 0.22 (0.12) 0.17 (0.12) 0.29 (0.14) 0.2 (0.14) 0.08 (0.09)
   Median (IQR) 0.22 (0.14, 0.29) 0.2 (0.12, 0.3) 0.18 (0.06, 0.28) 0.27 (0.2, 0.38) 0.18 (0.09, 0.29) 0.06 (0, 0.12)
Left SNh area predominance
   n (%) 32 (53.3%) 6 (46.2%) 6 (75.5%) 44 (54.2%) 45 (56.2%) 40 (70.2%)
   SN+, n (%) 39/71 (54.9%) 9/15 (60%) 4/11 (36.4%) 69/93 (74.2%) 31/73 (42.5%) 8 (8.8%)
Table 1. Demographical, clinical and ultrasound characteristics of patients (as per phenotype) and controls. 
ALS: amyotrophic lateral sclerosis; BMI: body mass index; cALS: classical ALS; EB: executive or behavioural; 
FTD: frontotemporal dementia; OMD: other movement disorders (atypical parkinsonism, vascular 
parkinsonism and essential tremor); PD: Parkinson’s disease; PLS: primary lateral sclerosis; PMA: progressive 
muscular atrophy; SNh: hyperechogenicity of substantia nigra; SN+: hyperechogenicity of substantia nigra 
area > 0.22 cm2; UMN: upper motor neuron.
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SNh could reflect a gender-mediated differential vulnerability to certain diseases. However, this result must be 
taken cautiously because of the small number of studied PLS patients. Moreover, differences by gender could also 
be the result of a lower ultrasound penetration rate in women than men.
We found that left SNh side was larger in each cohort of patients and controls, but found no relationship 
between side of onset or side of symptoms predominance and the area of contralateral SNh. A larger SNh area 
contralateral to disease predominance has been found in PD5, but not in ALS8. Nor has SNh area been observed to 
correlate with the degree of clinical or subclinical impairment in PD patients, which suggests that SNh size does 
not actually reflect the degree of neuronal degeneration5, 29. Up to now, to the best of our knowledge, no study 
has compared the right with the left SNh area. However, in those studies reporting SNh sizes on both sides in 
large cohorts of PD patients and healthy controls, the reported left SNh area has almost always been larger than 
the right one24, 27, 30–32. It could be argued that side-related variations in the SNh area are explained by changes 
in the probe placement on the right and left side. Indeed, shifts in the position and angle of the probe can cause 
variations in the size of midbrain or midbrain structures. However, different studies, with diverse sonographers 
have found similar results24, 27, 30–32. Moreover, side differences remained stable when accounting for the area of 
the ipsilateral mesencephalon31, 32, suggesting that they cannot be explained by variations of the imaged midbrain. 
Finally, previous MRI studies in healthy individuals have also found larger iron deposits in different structures 
of the left brain hemisphere, including the SN33, 34. All this suggests that technical issues are not responsible for 
the differences between left and right sides. The fact that, in our study, this SNh side predominance was found in 
healthy individuals and patients with different diseases suggests that genetic or constitutional factors (e.g., hand-
edness), but not disease-related factors, could underlie these differences. Interestingly, an increased dopamine 
metabolism has been found in the left SN34 and handedness seem to influence the side of onset and predomi-
nance of impairment in ALS and PD35, 36. Considering this and the overall predominance of right-handedness 
in the population, the left SNh area predominance found in our study could reflect an increased vulnerability of 
the left-brain hemisphere in right-handed individuals due to an increased dopamine metabolism as previously 
suggested33, 34, what ultimately results in an asymmetric onset or impairment of the disease. However, further 
studies in right- and left-handed patients and controls are warranted to test the influence of handedness in SNh.
In the multivariate analysis, we found that fALS, but not history of other neurodegenerative diseases, was 
associated with a larger SNh area in ALS patients. This effect appeared independent of the identified mutation. 
Figure 1. SNh area in different subgroups of patients and controls according to the SNh side and to gender. 
ALS: amyotrophic lateral sclerosis; OMD: other movements disorders (atypical parkinsonism, vascular 
parkinsonism and essential tremor); PD: Parkinson’s disease; SNh: hyperechogenicity of the substantia nigra.
Estimate Lower 0.95 Upper 0.95 p
ALS 0.14 0.11 0.169  < 0.001**
PD 0.196 0.167 0.225  < 0.001**
OMD 0.11 0.078 0.141  < 0.001**
Left SNh 0.029 0.016 0.042  < 0.001**
Male gender 0.047 0.025 0.07  < 0.001**
Age 0.001 0 0.002 0.135
Table 2. Mixed lineal regression model that analyses differences in the SNh area between controls and 
subgroups of patients. ALS: amyotrophic lateral sclerosis; OMD: other movement disorders (atypical 
parkinsonism, vascular parkinsonism and essential tremor); PD: Parkinson’s disease; SNh: hyperechogenicity of 
substantia nigra.
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In PD, SNh+ has been associated with family history of PD in healthy subjects24 and has been found in the 
pre-symptomatic carriers of mutations that cause PD5. Furthermore, SNh+ healthy subjects have an increased 
risk of PD after a 5-year follow-up37. Altogether this suggests that SNh is a marker of genetic factors that predis-
pose to PD5, 24. Our results are consistent with those in PD and suggest that the Mendelian forms of ALS are also 
predisposed to SNh. Conversely, family history of PD or dementia was not associated with larger SNh in ALS, 
suggesting that in sALS other non-genetic factors influence the SNh size.
We found no influence of ageing in SNh area. Previous studies in healthy subjects and patients have reported 
conflicting results5, 24, 31, 32. Although SNh can be found even in early childhood32, it seems that a mild increase 
in SNh area in both adolescence and very old subjects (>75 years) can occur5, 31, 32. However, during adulthood 
(30–75 years old) the SNh area remains more or less stable5, 24, 31, 32, which agrees with our results.
Altered ferritin levels have been found in ALS patients and associated with poor prognosis38 and could indi-
rectly reflect brain iron deposits. However, we found no correlation between ferritin levels and SNh area. We 
neither found correlation of executive or behavioural scores with SNh area.
Low premorbid BMI has been associated with a higher risk of ALS, and genetic factors could underlie this 
relationship39. Nevertheless, we found no association between SNh and premorbid BMI either.
SN− (n = 42) SN+(n = 55)
Age (years)
  Mean (SD) 57.35 (12.84) 62.68 (11.48)
  Median (IQR) 57.45 (47.65, 68.2) 62.97 (56.54, 71.55)
Gender (male)
  n (%) 20 (62.5%) 41 (74.5%)
Body mass index, n = 102
  Mean (SD) 27.22 (4.49) 27.18 (4.3)
  Median (IQR) 26.53 (24.54, 29.76) 26.53 (23.98, 29.76)
Family history 7 (16.7%) 18 (32.7%)
  Dementia n (%) 1 (3.1%) 8 (14.5%)
  PD n (%) 1 (3.1%) 2 (3.6%)
  Dementia and PD n (%) 2 (6.2%) 0 (0%)
  ALS or FTD n (%) 3 (9.4%) 8 (14.5%)
Region of onset
  Bulbar n (%) 6 (18.8%) 15 (27.3%)
  Spinal n (%) 26 (81.2%) 40 (72.7%)
Parkinsonism
  n (%) 1 (2.4%) 3 (5.5%)
Time from onset (months)
  Mean (SD) 36.45 (46.83) 32.58 (32.2)
  Median (IQR) 15.58 (8.43, 55.51) 21.6 (13.62, 42.77)
ALSFRS-R
  Mean (SD) 34.06 (8.55) 35.41 (7.53)
  Median (IQR) 34.5 (31, 40.5) 36.5 (31.25, 41.75)
UMN score
  Mean (SD) 5.78 (5.94) 4.75 (5.11)
  Median (IQR) 3.5 (0, 12.25) 2.5 (1, 9)
EB impairment (n = 80)
  No 21 (72.4%) 30 (58.8%)
  Mild 8 (27.6%) 19 (37.3%)
  FTD 0 (0%) 2 (3.9%)
  Familial or genetic ALS, n (%) 3 (9.37%) 9 (16.36%)
  C9ORF72, n (%) 1 (3.12%) 6 (10.91%)
  SOD1, n (%) 1 (3.12%) 3 (5.45%)
  Unknown, n (%) 1 (3.12%) 0 (0%)
Ferritin ug/L
  Mean (SD) 195.31 (155.14) 192.31 (128.31)
  Median (IQR) 154 (68, 311) 155 (105.25, 240.25)
Table 3. Demographical, clinical and analytical characteristics of ALS patients classified according to the 
predefined threshold of SNh area (0.22 cm2). ALS: amyotrophic lateral sclerosis; BMI: body mass index; EB: 
executive or behavioural; FTD: frontotemporal dementia; PD: Parkinson’s disease; SNh: hyperechogenicity 
of the substantia nigra; SN+: area of hyperechogenicity of one substantia nigra > 0.22 cm2; SN−: area of 
hyperechogenicity of both substantia nigra ≤0.22 cm2; UMN: upper motor neuron.
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Finally, no association between the clinical variables (ALSFRS-R, disease duration, cognitive or behavioural 
impairment or parkinsonism) and SNh area was found, although very few patients exhibited parkinsonism 
and this result must be taken cautiously. Our results agree with previous reports that have found no association 
between SNh or SNh+ and ALSFRS-R, disease duration or ALS subtype (bulbar or spinal)6–9. Similarly, in PD, 
most studies have observed no association between SNh and clinical variables5.
Strengths and limitations. Our study represents the largest and most thorough study of SNh in different 
neurodegenerative diseases and in controls conducted to date. We studied phenotypes (PMA and PLS) and var-
iables that have not been analysed before. We also introduced several methodological improvements compared 
to previous studies. Firstly, most reports consider SNh to be a dichotomous variable (SNh+ and SNh−). Despite 
SNh+ being arbitrarily defined (percentile 90 of healthy subjects), it can be useful as a diagnostic biomarker. 
However, when the aim is to study the factors that contribute to SNh, dichotomising a biological variable that is 
in fact continuous is not methodologically sound. Secondly, in order to increase the statistical power and to avoid 
unnecessary data loss, we included data of both SNh sides in the inferential analysis. To date, all studies have 
either considered only the biggest SNh or analysed the mean SNh, which does not reflect the anatomic basis. Our 
data show that SNh is unequally distributed between sides. Consequently, not considering this item in inferential 
studies can be a source of bias. Thirdly, previous reports had studied the correlation of clinical variables and SNh 
in ALS, but had not accounted for confounding factors. We performed a multivariate analysis and, consequently, 
our results are more reliable.
However, our study also has some limitations. Firstly, the sample size for some studied variables (fALS, PLS 
phenotype or parkinsonism) was small as their prevalence is low, so the results on these items must be taken cau-
tiously. Secondly, no sample size calculation was made and the overall number of included ALS patients could be 
insufficient for the number of studied variables. This could have limited the statistical power in the multivariate 
analysis and, consequently, some of the variables that show an association trend could also have some influence 
on SNh. Thirdly, the medical records of the ALS patients’ relatives were not systematically reviewed. This could 
introduce a recall bias since patients could be more likely to become aware of a family history of ALS than one of 
other neurodegenerative diseases. Therefore, the influence of family history of dementia and PD could have been 
underestimated herein. However, these limitations do not invalidate the positive results.
Figure 2. SNh area on the left and the right side in sporadic or familial ALS patients harbouring mutations 
(“C9ORF72” and “SOD1”), familial ALS without known mutations (“Unknown”) and sporadic patients not 
carrying mutations (“NO”). SNh: hyperechogenicity of the substantia nigra.
Estimate Std. Error Lower 95% Upper 95% P-value
PMA −0.006 0.029 −0.063 0.051 0.831
PLS −0.067 0.034 −0.135 0.001 0.055
History of PD 
or dementia 0.006 0.029 −0.05 0.063 0.824
Age 0.001 0.001 0 0.003 0.163
Male gender 0.036 0.023 −0.009 0.082 0.119
fALS 0.083 0.031 0.021 0.145 0.01*
Left SNh 0.022 0.012 −0.001 0.045 0.066
Tablee 4. Mixed lineal regression model that analyses the factors that contribute to the SNh area. fALS: 
familial ALS; PLS: primary lateral sclerosis; PMA: progressive muscular atrophy; PD: Parkinson’s disease; SNh: 
hyperechogenicity of substantia nigra.
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Conclusions
We show that left side and male gender are risk factors for SNh in both controls and different diseases. We report 
for the first time that fALS and ALS-causing mutations (C9ORF72 and SOD1), but not other disease-related 
variables, are major contributors to SNh. Finally, we demonstrate that SNh can also be found in PMA, and less 
frequently in PLS. Although the number of fALS, PMA and PLS patients included was small, based on our results 
and previous reports in both patients and healthy subjects, we hypothesise that SNh is a marker of some constitu-
tional (male gender, handedness) or genetic vulnerability factors for neuronal degeneration that extend beyond 
the nigrostriatal system. Remarkably, reduced intracortical inhibition within the motor cortex, as assessed by 
transcranial magnetic stimulation, which is an early feature in ALS and PD40, has also been reported in healthy 
subjects with SNh41, further supporting this vulnerability hypothesis. Larger studies in both healthy populations 
and presymptomatic individuals and patients who carry ALS mutations are warranted to confirm our results and 
hypotheses.
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